Jet production in ep collisions

Results obtained by the H1 and ZEUS Collaborations on jet production in photoproduction and deep-inelastic scattering are presented and compared to NLO QCD models.Comment: 5 pages, 5 figures, talk given at the XXXVIIIth Rencontres de Moriond (QCD), Les Arcs, France, March 22-29 200

A Very Forward Proton Spectrometer for H1

A new, very forward, proton spectrometer with large acceptance will be installed in the proton beam line of the H1 experiment in 2003. The spectrometer, located 220 m downstream of the interaction point, is based on the Roman Pot technique and consists of two stations in the cold section of the proton beam line. A brief description of this new device and expected physics results are presented.Comment: 15 pages, 8 figures, talk given at LISHEP 2002, Session C: Workshop on Diffractive Physics, 4-8 February 2002, Rio de Janeiro, Brazi

Single inclusive jet production and the nuclear modification ratio at very forward rapidity in proton-lead collisions with sNN\sqrt{s_{NN}} = 5.02 TeV

We present calculations of single inclusive jet transverse momentum and energy spectra at forward rapidity ($5.2\!<\!y\!<\!6.6$) in proton-lead collisions with $\sqrt{s_{NN}}$ = 5.02 TeV. The predictions are obtained with the KaTie Monte Carlo event generator, which allows to calculate interactions within the High Energy Factorisation framework. The tree-level matrix element results are subsequently interfaced with the CASCADE Monte Carlo event generator to account for hadronisation. The effects of the saturation of the gluon density, leading to suppression of the cross section, are investigated.Comment: 10 page

Deep inelastic diffractive scattering at HERA

Recent high precision measurements of deep inelastic diffractive scattering at HERA are presented in an increased region of phase space. Current models for diffractive photon dissociation are compared to the data.Comment: 6 pages, 6 figures, talk presented at QCD03, Montpellier, France, July 2-9, 200

Study protocol of European Fans in Training (EuroFIT):a four-country randomised controlled trial of a lifestyle program for men delivered in elite football clubs

Background: Lifestyle interventions targeting physical activity, sedentary time and dietary behaviours have the potential to initiate and support behavioural change and result in public health gain. Although men have often been reluctant to engage in such lifestyle programs, many are at high risk of several chronic conditions. We have developed an evidence and theory-based, gender sensitised, health and lifestyle program (European Fans in Training (EuroFIT)), which is designed to attract men through the loyalty they feel to the football club they support. This paper describes the study protocol to evaluate the effectiveness and cost-effectiveness of the EuroFIT program in supporting men to improve their level of physical activity and reduce sedentary behaviour over 12 months. Methods: The EuroFIT study is a pragmatic, two-arm, randomised controlled trial conducted in 15 football clubs in the Netherlands, Norway, Portugal and the UK (England). One-thousand men, aged 30 to 65 years, with a self-reported Body Mass Index (BMI) ≥27 kg/m2 will be recruited and individually randomised. The primary outcomes are objectively-assessed changes in total physical activity (steps per day) and total sedentary time (minutes per day) at 12 months after baseline assessment. Secondary outcomes are weight, BMI, waist circumference, resting systolic and diastolic blood pressure, cardio-metabolic blood biomarkers, food intake, self-reported physical activity and sedentary time, wellbeing, self-esteem, vitality and quality of life. Cost-effectiveness will be assessed and a process evaluation conducted. The EuroFIT program will be delivered over 12 weekly, 90-minute sessions that combine classroom discussion with graded physical activity in the setting of the football club. Classroom sessions provide participants with a toolbox of behaviour change techniques to initiate and sustain long-term lifestyle changes. The coaches will receive two days of training to enable them to create a positive social environment that supports men in engaging in sustained behaviour change. Discussion: The EuroFIT trial will provide evidence on the effectiveness and cost-effectiveness of the EuroFIT program delivered by football clubs to their male fans, and will offer insight into factors associated with success in making sustained changes to physical activity, sedentary behaviour, and secondary outcomes, such as diet.Trial registration: ISRCTN: 81935608. Registered 16 June 2015.<br/

First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes

: Background : Type 1 diabetes (T1D) is a CD4+ T cell-driven autoimmune disease characterized by the destruction of insulin-producing pancreatic β-cells by CD8+ T cells. Achieving glycemic targets in T1D remains challenging in clinical practice; new treatments aim to halt autoimmunity and prolong β-cell survival. IMCY-0098 is a peptide derived from human proinsulin that contains a thiol-disulfide oxidoreductase motif at the N-terminus and was developed to halt disease progression by promoting the specific elimination of pathogenic T cells. Methods: This first-in-human, 24-week, double-blind phase 1b study evaluated the safety of three dosages of IMCY-0098 in adults diagnosed with T1D < 6 months before study start. Forty-one participants were randomized to receive four bi-weekly injections of placebo or increasing doses of IMCY-0098 (dose groups A/B/C received 50/150/450 μg for priming followed by three further administrations of 25/75/225 μg, respectively). Multiple T1D-related clinical parameters were also assessed to monitor disease progression and inform future development. Long-term follow-up to 48 weeks was also conducted in a subset of patients. Results: Treatment with IMCY-0098 was well tolerated with no systemic reactions; a total of 315 adverse events (AEs) were reported in 40 patients (97.6%) and were related to study treatment in 29 patients (68.3%). AEs were generally mild; no AE led to discontinuation of the study or death. No significant decline in C-peptide was noted from baseline to Week 24 for dose A, B, C, or placebo (mean change − 0.108, − 0.041, − 0.040, and − 0.012, respectively), suggesting no disease progression. Conclusions: Promising safety profile and preliminary clinical response data support the design of a phase 2 study of IMCY-0098 in patients with recent-onset T1D. Trial registration: IMCY-T1D-001: ClinicalTrials.gov NCT03272269; EudraCT: 2016–003514-27; and IMCY-T1D-002: ClinicalTrials.gov NCT04190693; EudraCT: 2018–003728-35

Performance studies of the final prototype for the CASTOR forward calorimeter at the CMS experiment

We present performance results of the final prototype for the CASTOR quartz-tungsten sampling calorimeter, to be installed in the very forward region of the CMS experiment at the LHC. The energy linearity and resolution, the uniformity, as well as the spatial resolution of the prototype to electromagnetic and hadronic showers are studied with $E=$ 10--200 GeV electrons, $E=$ 20--350 GeV pions, and $E=$ 50, 150 GeV muons in beam tests carried out at CERN/SPS in 2007

Measurement of differential cross sections for top quark pair production using the lepton plus jets final state in proton-proton collisions at 13 TeV

National Science Foundation (U.S.